Vaxcyte has advanced to the Phase II trial’s second and final stage (Stage 2) assessing its 31-valent pneumococcal conjugate ...

Operator Good day, everyone and welcome to Pfizer's fourth-quarter 2024 earnings conference call. Today's call is being ...

Q4 2024 Earnings Conference Call February 4, 2025 10:30 AM ETCompany ParticipantsFrancesca DeMartino - Senior Vice President, ...

In the U.S., Dupixent continued its leadership in New to Brand prescriptions ... the start of six new vaccine studies, including the Phase 3 study for a pneumo vaccine PCV-21 in children.

Sanofi has received China’s National Medical Products Administration (NMPA) approval for the use of Sarclisa (isatuximab), ...

Growth of Prevnar has been driven lately by use in adults, however, and it is here that Pfizer is facing a challenge from Merck and its V114 pneumococcal conjugate vaccine candidate. The Prevnar ...

For now, however, the Prevnar brand remains largely unscathed ... "Despite the availability of current pneumococcal conjugate vaccines, many adults remain vulnerable to pneumococcal disease ...

A small, early trial of a vaccine that mobilizes the immune system to battle advanced kidney cancers appears successf ...

Merck MRK announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of its 21-valent pneumococcal conjugate vaccine ...

A personalized neoantigen cancer vaccine generated strong immune responses in renal cell carcinoma patients, leading to ...

Neoantigen-targeting personalized cancer vaccines (PCVs) are highly immunogenic in high-risk clear cell renal cell ca ...